BOSTON – Mursla Bio has announced the commercial launch of its new AI Precision Medicine Platform, designed to dramatically enhance non-invasive diagnostic capabilities by isolating organ-specific extracellular vesicles (EVs) from small blood samples. The launch is supported by a new pre-print study validating the technology for liver disease applications, developed in collaboration with Evotec International GmbH and University College London.
The platform offers a breakthrough in liquid biopsy by enabling access to biologically labeled, organ-specific multi-omics data from just 2ml of plasma. By isolating EVs secreted into the bloodstream by specific organs, Mursla’s platform overcomes the signal noise typical in bulk EV analysis, reducing background interference by up to five orders of magnitude. This leads to higher-resolution data and better performance of AI-powered prediction models.
The pre-print study highlights the first validated method for isolating hepatocyte-derived EVs from human plasma. It confirms liver origin through proteomic and nucleic acid profiling, showcasing the platform’s ability to generate robust multi-omics data with minimal blood volume. The work was supported by proteomics data from Evotec and patient samples from University College London, with liver disease expert Professor Brian Davidson serving as a co-author.
Mursla Bio’s platform integrates advanced multi-omics workflows, embedded AI pipelines, and regulatory-aligned IVD translation steps to convert complex biological data into clinical-grade diagnostic assays. These assays, which are compatible with standard commercial instruments, use patented protocols similar to PCR and ELISA, facilitating easy adoption in clinical settings.
The platform is also the foundation for EvoLiver™, Mursla’s lead clinical program targeting early detection of hepatocellular carcinoma in patients with cirrhosis. Built from data across more than 300 patients, EvoLiver has demonstrated 86% sensitivity and 88% specificity in a locked, IVD-ready format and has received Breakthrough Device Designation from the U.S. FDA.
“EVs are nature’s native signal enrichment system for long-distance communication between cells and organs,” said Pierre Arsène, Founder and CEO of Mursla Bio. “Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.”
Looking ahead, Mursla Bio is extending its platform to include organ programs in cardiometabolic, lung, and neurological conditions. The company aims to support pharmaceutical development through enhanced patient stratification, therapeutic monitoring, surrogate biomarker identification, and molecular phenotyping.
